Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01043523 · ClinicalTrials.gov registry record
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 52
- Enrollment target
NCT01043523 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 52 participants.
The verdict
NCT01043523 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years. Data that has been recorded in the child's medical records relating to the injection of Primovist/Eovist will be collected. Information will be collected from up to 2 weeks before the child received Primovist/Eovist until 12 months after the child received Primovist/Eovist. Copy of the child's MR images that were taken right before and after the child received Primovist/Eovist and all other reports (laboratory reports, other imaging reports, etc) that are part of the child's medical records during that time period will be collected.
Interventions
- DRUG Gadoxetic Acid Disodium (Eovist, BAY86-4873)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01043523
The ClinicalTrials.gov registry entry for NCT01043523 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gadoxetic Acid Disodium (Eovist, BAY86-4873) is the first listed.
NCT01043523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01043523 about?
NCT01043523 is a clinical study titled "Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.". Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years. Data that has been recorded in the child's medical records relating to the injection of Primovist/Eovist...
What is the current status of trial NCT01043523?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2009-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01043523?
The interventions under investigation include: Gadoxetic Acid Disodium (Eovist, BAY86-4873) (DRUG).
Who is sponsoring clinical trial NCT01043523?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.